Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to ... (zophrenia. Depot formulationsshould be c...)

Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months

Date:9/2/2008

zophrenia. Depot formulations should be considered as a treatment option when a patient expresses a preference for such treatment due to convenience or if it is determined that a depot formulation is necessary to help avoid nonadherence to oral medications.(2)

Long-acting antipsychotic formulations have been associated with improved treatment adherence and reduced treatment failures.(3) By administering long- acting medications, healthcare professionals know when patients have received their medication and can immediately detect non-adherence when a patient fails to return for a scheduled injection.(4) Different from both oral and injected short-acting formulations, long-acting formulations of antipsychotics allow for stable concentrations of the active drug to remain at a therapeutic range for an extended period of time.(5)

About Schizophrenia

Schizophrenia is a severe and debilitating illness with symptoms such as delusions (false beliefs that cannot be corrected by reason), hallucinations (usually in the form of non-existent voices or visions), disorganized speech and severe disorganized or catatonic behavior. These signs and symptoms are associated with marked social or occupational dysfunction. Features of schizophrenia consist of characteristic signs and symptoms that have been present for a significant portion of time during a one-month period, with some signs of the disorder persisting for at least six months.(6) In addition to these symptoms, patients with schizophrenia are at greater risk for medical comorbidities than the general population.

About Olanzapine

Since olanzapine was introduced in 1996, it has been prescribed to approximately 24 million people worldwide. Olanzapine is not recommended for use in patients under 18 years of age.

In Europe, olanzapine is indicated for schizophrenia and in clinical trials, it has shown to be effective in maintaining the clinical improvement during continuation therapy in pa
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
2. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
3. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
4. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
5. New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
6. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
7. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
8. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
9. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
10. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

Post Your Comments:

(Date:12/15/2009)... -- The U.S. Food and Drug Administration (FDA) Endocrinologic ... yes, 4 no, and 1 abstention that AstraZeneca has ... support the use of CRESTOR® (rosuvastatin calcium) in individuals ... or equal to 50 years, women greater than or ... 130 mg/dL; hsCRP greater than or equal to 2.0 ...

(Date:12/15/2009)... MONICA, Calif., Dec. 15 Dakim, Inc. and ... Thanks for Loved Ones, Brain Health Contest, designed to ... symptoms of dementia and Alzheimer,s disease. All five winners ... product designed specifically to help seniors preserve their brain ... kind in senior living communities across the country. ...

(Date:12/15/2009)... Flextronics (Nasdaq: FLEX ) today ... announced acquisition of SloMedical S.R.O., a leading ... from tubing sets to complex devices for ... provides a broad set of capabilities to ... Terms of the deal were not disclosed. ...

Breaking Medicine Technology:Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2 Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3 Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4 Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5 5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 2 5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3 Flextronics Completes SloMedical Acquisition 2 Medical Heroin Helps Treatment Resistant Addicts 54920 1 Medical Heroin Helps Treatment Resistant Addicts 54920 2 Medical Heroin Helps Treatment Resistant Addicts 54920 3 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 1 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 2 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 3 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 4 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 5 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 6 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 7 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 8 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 9 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 10 LSUHSC research discovers new targets for treatment of invasive breast cancer 54910 1 LSUHSC research discovers new targets for treatment of invasive breast cancer 54910 2

[0] Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study [0] 5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's [0] Flextronics Completes SloMedical Acquisition

... 6 Four studies highlighting late-breaking research advances in the ... today at the 50th Annual Meeting of the American Society ... , Results from a study examining the ability ... in the inner lining of blood vessels, in patients with ...

... FRANCISCO, Dec. 6 Researchers today report that ... erythropoiesis-stimulating agents (ESAs), a significantly greater proportion of ... who received ESAs needed blood transfusions and utilized ... patients who received ESAs prior to implementation of ...

Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion

(Date:12/16/2009)... holidays are rapidly approaching and what would be the perfect gift ... cells, of course! Celebrity Beauty Engineer® and Licensed Esthetician Mary Schook ... to look and feel their best! , ... (PRWEB) ... kind of gift does a person get that special woman who ...

(Date:12/15/2009)... have successfully developed a new electrophoretic method for ... blood. The technique, using SARCOSYL-PAGE, has specifically ... the performance characteristics of SDS-PAGE for detecting other ... a grant from the World Anti-Doping Agency (WADA), ... Testing and Analysis published by Wiley-Blackwell. , ...

(Date:12/15/2009)... State Authority, Ban on Annual Benefit Limits, & ... Consumer Watchdog condemned the removal of ... and the public option from the U.S. Senate ... the Senate must still make three essential fixes ... the entire health care system to the insurance ...

(Date:12/15/2009)... Palo Alto Networks(TM), the network security ... its PA-4000 Series next-generation firewalls for accurate threat ... visibility and control over applications such as peer-to-peer ... national university with eight facilities on five campuses. ... a number of academic schools and institutions throughout ...

(Date:12/15/2009)... Lady of Lourdes Health Care Services Inc., the parent ... pay the United States $7.95 million to resolve allegations ... today. The two hospitals are Our Lady of Lourdes ... Center of Burlington County (LMC) in Willingboro, N.J. ... by a whistleblower, Tony Kite, in 2005. The lawsuit ...

Breaking Medicine News(10 mins):Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2 Health News:Researchers discover novel method for detecting MIRCERA 2 Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2 Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3 Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4 Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5 Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2 Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3 Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2

[0] New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything [1] Researchers discover novel method for detecting MIRCERA [1] The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System [1] Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University [0] Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations

... neurological reward responses , MONDAY, Dec. 3 (HealthDay News) ... brain activity patterns than those who,ve never had the ... at the University of Pittsburgh School of Medicine used ... women who,d recovered from anorexia -- defined as maintaining ...

... are clumps of fiber-like misfolded proteins which many ... , While effective treatment remains an elusive goal, ... chemists suggests a possible new approach. , ... students managed to capture and characterize a crucial ...

... Crawford brings more than 30 years of experience in Public Safety ... ... ESi(R), the global leader in,crisis information management technology, today announced ... Northeast.,Crawford is based in Boston, where he is responsible for ESi ...

... conference to discuss new Medicaid generic prescription drug,reimbursement rule ... use his,power to make sure the legislative fix is ... to be fully implemented in early,2008, will grossly underpay ... Brad Hall, Executive Director of the Kentucky Pharmacists ...

... 3 inVentiv Health, Inc.,(Nasdaq: VTIV ) today ... be held Tuesday, December 11th, 2007 in New York ... 9:00 a.m. as announced earlier, and,will conclude at noon, ... business overview, presentations by the,leaders of each of the ...

... ReBuilder Medical,Technologies, Inc. (Pink Sheets: RBRM), developers ... peripheral neuropathy, Molluscum,Contagiosum, and MRSA announces record profits ... ), "Corporate profits increased by 100% over ... disclosure will be released on our annual report,in ...

Other Medicine News:Health News:Brain Activity Points to Origins of Anorexia 2 Health News:UIC chemists characterize Alzheimer's neurotoxin structure 2 Health News:ESi Announces Strategic New Hire in Boston 2 Health News:Kentucky Pharmacists Event Urging Senate Minority Leader McConnell to Fix Flawed Medicaid Drug Reimbursement Rule 2 Health News:inVentiv Health Provides Updated Information on December 11th Investor Day 2 Health News:inVentiv Health Provides Updated Information on December 11th Investor Day 3 Health News:ReBuilder Medical Technologies, Inc. Reports Doubled Profits for October 2

Brain Activity Points to Origins of Anorexia UIC chemists characterize Alzheimer's neurotoxin structure ESi Announces Strategic New Hire in Boston Kentucky Pharmacists Event Urging Senate Minority Leader McConnell to Fix Flawed Medicaid Drug Reimbursement Rule inVentiv Health Provides Updated Information on December 11th Investor Day ReBuilder Medical Technologies, Inc. Reports Doubled Profits for October

Four 62 mirrors give a 360 view of the anterior chamber angle with only a slight lens rotation. Posterior pole can be viewed through center of lens....

Two opposing 62 mirrors provide a complete view of the anterior chamber angle with only a 180 lens rotation. Methylcellulose and no methylcellulose designs available....

Lacrimal cannula blunt tip with 0.3 mm side port, straight....

McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....

Medicine Products:

Ocular Thorpe Four Mirror Gonio Ocular Two Mirror Gonio Mcintyre Cannula McIntyre Lacrimal Cannula

Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to ...(zophrenia. Depot formulationsshould be c...),Health